Advanced search
Publication Cover
Leukemia & Lymphoma Volume 48, 2007 - Issue 3
Submit an article Journal homepage
22
Views
1
CrossRef citations to date
0
Altmetric
Commentary

What is the optimal prognostic tool for the assessment of patients with newly diagnosed follicular lymphoma?

Philippe Solal-Celigny Centre Jean Bernard, Le Mans, FranceCorrespondence[email protected]
Pages 452-453 | Published online: 01 Jul 2009

References

  • Etto L Y, Silva V C, Inaoka R J, Costa R P, Alves A C, Colleoni G WB. Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients?. Leuk Lymphoma 2007; 48((3))526–530
  • Gascoyne R D, Adomat S A, Krajewski S, Krajewska M, Horsman D, Tolcher A, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin lymphoma. Blood 1997; 90: 244–251
  • Hermine O, HaÏoun C, Lepage E, d'Agay M F, Briere J, Lavignac C, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996; 87: 265–272
  • Perea G, Altès A, Montoto S, Domingo-Doménech E, Fernández-Sevilla A, Ribera J M, et al. Prognostic indexes in follicular lymphoma: A comparison of different prognostic systems. Ann Oncol 2005; 16: 1508–1513
  • Arcaini L, Colombo N, Passamonti F, Burcheri S, Orlandi E, Brusamolino E, et al. Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leuk Res 2006; 30: 277–282
  • Fischer R I, Le Blanc M, Press O W, Maloney D, Unger J, Miller T. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447–8452
  • Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
  • Colocci N, Weller E, Hochster H S, Gasgoyne R, Kumm B, Ryan T, et al. Prognostic significance of the Follicular Lymphoma International Prognostic Index in the E1496 trial of chemotherapy with or without rituximab maintenance. J Clin Oncol 2005; 23: 566S
  • Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504–1508
  • Sehn L. Optimal use of prognostic factors in non-Hodgkin lymphoma. Hematology (Am Soc Hematol Educ Program) 2006; 295–302

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.